FDA Plays

[alexander77]

EDAP:According to the AF-rule,EDAP should be $12/share.

According to Adam Feuerstein, every biotech company which has an oncology drug in phase 3 and which is nearing FDA decision should have a market cap of 300M at least. I presume this should be also for medical device companies like EDAP, especially when it already approved in Europe and from which the treatment is already reimbursed in France. So with a current market cap of 80M dollar, the share price BEFORE FDA approval should be $12 at least. Please don't forget that this company made net profit last quarter

final FDA decision July 10th